



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 5/00	A2	(11) International Publication Number: WO 00/21979 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/JP99/05597 (22) International Filing Date: 8 October 1999 (08.10.99) (30) Priority Data: PP 6469 13 October 1998 (13.10.98) AU PP 9257 16 March 1999 (16.03.99) AU (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): MORI, Hiroaki [JP/JP]; 5-20-205, Ohmachi, Tsuchiura-shi, Ibaraki 300-0038 (JP). SAKAMOTO, Kazutoshi [JP/JP]; 17-14, Ottom-inami 2-chome, Tsuchiura-shi, Ibaraki 300-0845 (JP). TSURUMI, Yasuhisa [JP/JP]; 3-19-1-3-301, Azuma, Tsukuba-shi, Ibaraki 305-0031 (JP). TAKASE, Shigehiro [JP/JP]; 1-12-10, Sousya, Ishioka-shi, Ibaraki 315-0016 (JP). HINO, Motohiro [JP/JP]; 13-3-1003, Touzaki-cho, Tsuchiura-shi, Ibaraki 300-0031 (JP).	(74) Agent: TAKASHIMA, Hajime; Yuki Building, 3-9, Hiranomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0046 (JP). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF		
(57) Abstract A cyclic tetrapeptide compound and use thereof. Especially, a compound WF27082, a process for production of the compound by culturing, in a nutrient medium, a WF27082-producing strain belonging to <i>Acremonium</i> and recovering the compound from a culture broth, a pharmaceutical composition containing the compound as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient, the compound for use as a medicament, a use of the compound for manufacture of a medicament for inhibiting histone deacetylase, a use of the compound for manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infections, organ transplant rejections, autoimmune diseases, or tumors, a use of histone deacetylase inhibitors as an immunosuppressant or an antitumor agent, and a use of histone deacetylase inhibitors for manufacture of a medicament for treating or preventing organ transplant rejections, autoimmune diseases or tumors are described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION**CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF****TECHNICAL FIELD**

The present invention relates to a cyclic tetrapeptide compound which is
5 useful as a medicament, to a process for producing the same and to a
pharmaceutical composition comprising the same.

BACKGROUND ART

Histone deacetylases are known to play an essential role in the
transcriptional machinery for regulating gene expression, and histone deacetylase
10 inhibitors induce histone hyperacetylation and affect the gene expression.
Therefore, a histone deacetylase inhibitor is useful as a therapeutical or
prophylactic agent for several diseases caused by abnormal gene expression, such
as inflammatory disorders, diabetes, diabetic complications, homozygous
thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal
15 infection, or the like.

In this connection, a cyclic tetrapeptide compound that can be used as an
anti-tumor agent is disclosed in JP-A-7-196686 but this publication is silent on
the action against histone deacetylases and the effect against the above-mentioned
various diseases.

20 DISCLOSURE OF INVENTION

The present invention relates to a novel cyclic tetrapeptide compound
WF27082 which is useful as a medicament, to a process for producing the same
and to a pharmaceutical composition comprising the same.

More particularly, it relates to a cyclic tetrapeptide compound which has a
25 potent inhibitory effect on the activity of histone deacetylase.

The inventors of this invention also found that a histone deacetylase inhibitor,
such as the WF27082, has a potent immunosuppressive effect and potent
antitumor effect. Therefore, a histone deacetylase inhibitor, such as WF27082, is
useful as an active ingredient of an immunosuppressant and an antitumor agent
30 and useful as a therapeutical or prophylactic agent for an organ transplant
rejection, autoimmune diseases, tumor, or the like.

Accordingly, one object of this invention is to provide a compound which has
biological activities as stated above.


Another object of this invention is to provide a process for the production of WF27082 by fermentation of a WF27082-producing strain belonging to the genus *Acremonium* in a nutrient medium.

A further object of this invention is to provide a pharmaceutical composition
5 containing, as an active ingredient, the WF27082.

A yet further object of this invention is to provide a use of the histone deacetylase inhibitors, such as WF27082, for treating and preventing diseases stated above.

Thus, the present invention provides the following.

10 (1) A WF27082 compound of the formula :



wherein R^1 is methyl, R^2 is methyl or ethyl, R^3 is hydrogen or methyl and R^4 is hydroxy optionally having a hydroxy-protective group, providing that when R^3 is hydrogen, R^2 is ethyl.

(2) A WF27082 compound of (1) above, wherein R^1 is methyl, R^2 is ethyl, R^3 is
15 methyl and R^4 is hydroxy.

(3) A fungal strain belonging to the genus *Acremonium*, which has a deposit number FERM BP-6539 and which produces a compound having a histone deacetylase inhibitory activity.

(4) A compound having a histone deacetylase inhibitory activity, which is
20 obtained by culturing the fungal strain of (3) above in a nutrient medium and recovering the compound from a culture broth thereof.

(5) A process for producing the WF27082 compound of (1) above, which comprises culturing, in a nutrient medium, a WF27082-producing strain

belonging to the genus *Acremonium* and recovering the compound from a culture broth thereof.

(6) The process of (5) above, wherein the WF27082-producing strain belonging to the genus *Acremonium* is the fungal strain of (3).

5 (7) A pharmaceutical composition containing the WF27082 compound of (1) above as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.


(8) A compound of (1) above for use as a medicament.

10 (9) A process for producing a compound having a histone deacetylase inhibitory activity, which comprises culturing, in a nutrient medium, a fungal strain belonging to the genus *Acremonium*, which produces a compound having a histone deacetylase inhibitory activity, and recovering said compound.

(10) A compound having a histone deacetylase inhibitory activity, which is obtained by culturing, in a nutrient medium, a fungal strain belonging to the

15 genus *Acremonium*, which produces a compound having histone deacetylase inhibitory activity, and recovering the compound from a culture broth thereof.

(11) A histone deacetylase inhibitor comprising a compound of the formula (I):




wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group.

20 (12) A method for inhibiting histone deacetylase, comprising using a compound (I) used in (11) above.

(13) A use of compound (I) used in (11) above for the manufacture of a medicament for inhibiting histone deacetylase.

- (14) A pharmaceutical composition for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections or autoimmune diseases, which comprises, as an active ingredient, a compound of the formula (I) wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group.
- (15) A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), or organ transplant rejections, autoimmune diseases, which comprises administering a compound (I) used in (14) above to a human being or an animal.
- (16) A use of a compound (I) used in (14) above for the manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections or autoimmune diseases.
- (17) A method for treating or preventing protozoal infections or tumors, which comprises administering a compound WF 27082 used in (1) above to a human being or an animal.
- (18) A use of a compound WF27082 used in (1) above for the manufacture of a medicament for treating or preventing protozoal infections or tumors.
- (19) A use of a histone deacetylase inhibitor as an immunosuppressant or an antitumor agent.
- (20) A use of a histone deacetylase inhibitor for the manufacture of a medicament for treating or preventing organ transplant rejections, autoimmune diseases or tumors.


The compound, which has a potent inhibitory effect on the activity of histone deacetylase, can be represented by the following formula (I):



wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group.

5

Of a series of these compounds, particularly the compound of the following formula is a novel compound.



wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group, providing that when R³ is hydrogen, R² is ethyl.

10

The compound of the present invention having the formula (I), wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally

having a hydroxy-protective group, providing that when R^3 is hydrogen, R^2 is ethyl, is also referred to as WF27082.

Particulars of the above definitions and the preferred embodiments thereof are explained in detail in the following.

5 The term "lower" used in the specification is intended to mean 1 to 6 carbon atoms, unless otherwise indicated.

Suitable hydroxy-protective group may include:

1-(lower alkylthio)(lower)alkyl such as lower alkylthiomethyl (e.g. methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.), and the like, in which the preferred one
10 may be C_1 - C_4 alkylthiomethyl and the most preferred one may be methylthiomethyl;

trisubstituted silyl such as tri(lower)alkylsilyl (e.g. trimethylsilyl, triethylsilyl, tributylsilyl, tert-butyl-dimethylsilyl, tri-tert-butylsilyl, etc.), lower alkyl-diarylsilyl
15 (e.g. methyl-diphenylsilyl, ethyl-diphenylsilyl, propyl-diphenylsilyl, tert-butyl-diphenylsilyl, etc.), and the like, in which the preferred one may be tri(C_1 - C_4) alkylsilyl and C_1 - C_4 alkyl-diphenylsilyl, and the most preferred one may be tert-butyl-dimethylsilyl and tert-butyl-diphenylsilyl;

acyl such as aliphatic acyl, aromatic acyl and aliphatic acyl substituted with
20 aromatic group, which are derived from carboxylic and sulfonic acids; and the like.

The aliphatic acyl may include lower alkanoyl which may have one or more suitable substituent(s) such as carboxy (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl, carboxyhexanoyl, etc.), cyclo(lower)alkyloxy(lower)alkanoyl which
25 may have one or more suitable substituent(s) such as lower alkyl (e.g. cyclopropyloxyacetyl, cyclobutyloxypropionyl, cycloheptyloxybutyryl, menthyloxyacetyl, menthyloxypropionyl, menthyloxybutyryl, menthyloxyheptanoyl, menthyloxyhexanoyl, etc.), camphorsulfonyl, and the like.

The aromatic acyl may include aroyl which may have one or more suitable
30 substituent(s) such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrophenyl, dinitrophenyl, nitronaphthoyl, etc.), arenesulfonyl which may have one or more suitable substituent(s) such as halogen (e.g. benzenesulfonyl, toluenesulfonyl, xylenesulfonyl, naphthalenesulfonyl, fluorobenzenesulfonyl,

chlorobenzenesulfonyl, bromobenzenesulfonyl, iodobenzenesulfonyl, etc.), and the like.

The aliphatic acyl substituted with aromatic group may include ar(lower)alkanoyl which may have one or more suitable substituent(s) such as lower alkoxy and trihalo(lower)alkyl (e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoromethyl-2-propoxy-2-phenylacetyl, etc.), and the like.

When the compound of the above formula (I) has stereoisomers, such isomers are also encompassed in the present invention. The compound of the formula (I) may form a salt, which is also encompassed in the present invention. For example, when a basic group such as an amino group is present in a molecule, an acid addition salt (e.g. salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like, salt with an organic acid such as methane sulfonic acid, fumaric acid, maleic acid, mandelic acid, citric acid, salicylic acid and the like) is exemplified, and when an acidic group such as carboxyl group is present, a basic salt (e.g. salt with a metal such as sodium, potassium, calcium, magnesium, aluminium and the like, a salt with amino acid such as lysine and the like) is exemplified. In addition, their solvates such as hydrate, ethanolate and the like are also encompassed in the present invention.

In this specification, the following designations of the specific compounds are conveniently used.

Compound name	R ¹	R ²	R ³	R ⁴
WF27082 B	-CH ₃	-CH ₂ CH ₃	-CH ₃	-OH
WF27082 E	-CH ₃	-CH ₂ CH ₃	-H	-OH
WF27082 F	-CH ₃	-CH ₃	-CH ₃	-OH
FR235220	-CH ₃	-CH ₃	-H	-OH

The WF27082 B has the following physico-chemical properties:

Molecular formula :



Molecular weight:

ESI-MS (+): m/z 557 (M + H)⁺

ESI-MS (-): m/z 555 (M - H)⁻

Specific rotation:

$[\alpha]_D(23^\circ\text{C}) -129^\circ$ (c=0.5, in chloroform)

5 Ultraviolet absorption spectrum:

λ max (methanol): 235 (sh)

λ max (methanol+0.01N HCl): 235 (sh)

λ max (methanol+0.01N NaOH): 235 (sh)

Solubility:

10 Soluble: methanol, chloroform, ethyl acetate, dimethyl sulfoxide

Insoluble: hexane

Color reaction

Positive: cerium sulfate reaction, iodine vapor reaction;
Dragendorff reaction

15 Negative: ninhydrin reaction, ferric chloride reaction, Molish reaction,
Ehrlich reaction

Thin layer chromatography (TLC):

	Stationary phase	Developing solvent	Rf value
	Silica Gel 60	chloroform:methanol	0.58
20	F254*	(20:1, v/v)	

* made by E. Merck

High performance liquid chromatography (HPLC):

Conditions:

Mobile phase: acetonitrile:water=50:50

25 Column: YMC ODS AM-303** (250 mm L. x 4.6 mm I. D.)

Flow rate: 1.0 ml/minute

Detection: UV at 210 nm

Retention time: 10.2 minutes

** made by YMC Co., Ltd.

30 Infrared spectrum:

ν max (neat): 3300, 2960, 2940, 2880, 1715, 1680, 1660, 1630, 1510,
1440, 1380, 1250, 1060 cm^{-1}

¹H Nuclear magnetic resonance spectrum:

(500 MHz, CDCl₃) δ H

7.52 (1H, d, J=10Hz, exchangeable), 7.30 - 7.17 (5H, m), 7.17 (1H, d, J=10Hz, exchangeable), 5.81 (1H, s, exchangeable), 5.16 (1H, m), 4.67 (1H, m), 4.26 - 4.16 (2H, m), 4.05 (1H, dd, J=10 & 7.5 Hz), 3.56 (1H, d, J=5Hz, exchangeable), 3.24 (1H, dd, J=13.5 & 10Hz), 2.96 (1H, dd, J=13.5 & 6Hz), 2.73 (1H, dd, J=10 & 8Hz), 2.62 (1H, m), 2.54 - 2.29 (4H, m), 2.16 (1H, m), 1.82 (1H, m), 1.66 - 1.56 (3H, m), 1.38 (3H, d, J=7Hz), 1.41 - 1.27 (5H, m), 1.28 (3H, s), 0.88 (3H, d, J=6.5Hz), 0.84 (3H, t, J=7Hz).

¹³C Nuclear magnetic resonance spectrum:

10 (125 MHz, CDCl₃) δ C

212.4 (s), 175.6 (s), 174.1 (s), 173.1 (s), 171.9 (s), 137.0 (s), 129.0 (d) x 2, 128.6 (d) x 2, 126.7 (d), 72.6 (d), 63.0 (s), 58.0 (d), 54.4 (d), 53.8 (t), 53.3 (d), 37.2 (t), 35.7 (t), 33.0 (t), 32.8 (d), 28.8 (t), 28.8 (t), 27.8 (t), 25.3 (t), 23.2 (t), 22.4 (q), 19.8 (q), 18.1 (q), 8.4 (q).

15 Property of the substance:

Neutral substance

The WF27082 E has the following physico-chemical properties:

Molecular formula :

20 C29H42N4O6

Molecular weight:

ESI-MS (+): m/z 543 (M + H)⁺

Specific rotation:

$[\alpha]_D(23^\circ\text{C}) -137^\circ$ (c=0.2, in chloroform)

25 Ultraviolet absorption spectrum:

λ max (methanol): 235(sh)

λ max (methanol+0.01N HCl): 235(sh)

λ max (methanol+0.01N NaOH): 235(sh)

Solubility:

30 Soluble: methanol, chloroform, ethyl acetate, dimethyl sulfoxide

Color reaction

Positive: cerium sulfate reaction, iodine vapor reaction,

Dragendorff reaction

Negative: ninhydrin reaction, ferric chloride reaction, Molish reaction,
Ehrlich reaction

Thin layer chromatography (TLC):

	Stationary phase	Developing solvent	Rf value
5	Silica Gel 60 F254*	chloroform:methanol (20:1, v/v)	0.46

* made by E. Merck

High performance liquid chromatography (HPLC):

Conditions:

- 10 Mobile phase: acetonitrile:water=50:50
Column: YMC ODS AM-303** (250 mm L. x 4.6 mm I. D.)
Flow rate: 1.0 ml/minute
Detection: UV at 210 nm
Retention time: 7.6 minutes

15 ** made by YMC Co., Ltd.

Infrared spectrum:

ν max (neat): 3300, 2940, 1720, 1690, 1660, 1630, 1530, 1460, 1420,
1380, 1320, 1250, 1150, 1060 cm^{-1}

^1H Nuclear magnetic resonance spectrum:

- 20 (500 MHz, CDCl_3) δ H
7.54 (1H, d, J=10Hz, exchangeable), 7.29 - 7.17 (5H, m), 7.10 (1H, d, J=10Hz,
exchangeable), 5.82 (1H, s, exchangeable), 5.19 (1H, m), 4.67 (1H, m), 4.26 - 4.17
(2H, m), 3.85 (1H, m), 3.54 (1H, br.s, exchangeable), 3.30 - 3.20 (2H, m), 2.96 (1H,
dd, J=14 & 6Hz), 2.54 - 2.38 (2H, m), 2.36 - 2.28 (2H, m), 2.18 - 2.12 (2H, m), 1.84
25 - 1.72 (3H, m), 1.67 - 1.57 (3H, m), 1.38 (3H, d, J=7Hz), 1.37 - 1.23 (4H, m), 1.28
(3H, s), 0.83 (3H, t, J=7Hz)

^{13}C Nuclear magnetic resonance spectrum:


- (125 MHz, CDCl_3) δ C
212.4 (s), 175.6 (s), 174.1 (s), 172.8 (s), 171.8 (s), 137.0 (s), 129.0 (d) x 2, 128.6 (d) x
2, 126.7 (d), 72.6 (d), 63.1 (s), 57.8 (d), 54.4 (d), 53.3 (d), 47.0(t), 37.3 (t), 35.8 (t),
30 28.8 (t), 28.7 (t), 27.9 (t), 25.3 (t), 25.0 (t), 24.7 (t), 23.2 (t), 22.4 (q), 19.8 (q), 8.4 (q).

Property of the substance :

Neutral substance

The WF27082 F has the following physico-chemical properties:

Molecular formula :



5 Molecular weight:

ESI-MS (+): m/z 543 (M + H)⁺

Specific rotation:

$[\alpha]_D(23^\circ\text{C}) -114^\circ$ (c=0.3, in chloroform)

Ultraviolet absorption spectrum:

10 λ max (methanol): 235(sh)
 λ max (methanol+0.01N HCl): 235(sh)
 λ max (methanol+0.01N NaOH): 235(sh)

Solubility:

Soluble: methanol, chloroform, ethyl acetate, dimethyl sulfoxide

15 Color reaction

Positive: cerium sulfate reaction, iodine vapor reaction,
 Dragendorff reaction

Negative: ninhydrin reaction, ferric chloride reaction, Molish reaction,
 Ehrlich reaction

20 Thin layer chromatography (TLC):

Stationary phase	Developing solvent	Rf value
Silica Gel 60	chloroform:methanol	0.47
F254*	(20:1, v/v)	

* made by E. Merck

25 High performance liquid chromatography (HPLC):

Conditions:

Mobile phase: acetonitrile:water=50:50

Column: YMC ODS AM-303** (250 mm L. x 4.6 mm I. D.)

Flow rate: 1.0 ml/minute

30 Detection: UV at 210 nm

Retention time: 7.6 minutes

** made by YMC Co., Ltd.

Infrared spectrum:

ν max (neat): 3300, 2930, 1720, 1690, 1660, 1630, 1530, 1440, 1390,
1280, 1180, 1120, 1060 cm^{-1}

^1H Nuclear magnetic resonance spectrum:

(500 MHz, CDCl_3) δ H

- 5 7.47 (1H, d, $J=10\text{Hz}$, exchangeable), 7.30 - 7.18 (5H, m), 7.17 (1H, d, $J=10\text{Hz}$,
exchangeable), 5.88 (1H, s, exchangeable), 5.14 (1H, m), 4.66 (1H, m), 4.26 - 4.14
(2H, m), 4.05 (1H, dd, $J=10$ & 8Hz), 3.54 (1H, d, $J=5\text{Hz}$, exchangeable), 3.27 (1H,
dd, $J=14$ & 10Hz), 2.94 (1H, dd, $J=14$ & 6Hz), 2.70 (1H, dd, $J=10$ & 8Hz), 2.61 (1H,
m), 2.53 - 2.35 (3H, m), 1.80 (1H, m), 1.78 (3H, s), 1.70 - 1.57 (3H, m), 1.40 - 1.25
10 (5H, m), 1.38 (3H, d, $J=7\text{Hz}$), 1.34 (3H, s), 0.86 (3H, d, $J=7\text{Hz}$)

^{13}C Nuclear magnetic resonance spectrum:

(125 MHz, CDCl_3) δ C

- 212.4 (s), 175.6 (s), 174.3 (s), 173.0 (s), 171.9 (s), 137.0 (s), 129.0 (d) x 2, 128.6 (d) x
2, 126.7 (d), 72.6 (d), 58.8 (s), 57.9 (d), 54.3 (d), 53.9 (t), 53.5 (d), 37.3 (t), 35.7 (t),
15 33.0 (t), 32.8 (d), 28.8 (t), 28.7 (t), 26.5 (q), 25.2 (t), 23.5 (q), 23.2 (t), 19.8 (q), 18.1 (q).

Property of the substance:

Neutral substance

- From the above physico-chemical properties and extensive studies, the
20 chemical structures of WF27082 B, E and F were respectively assigned as
mentioned above.

- The WF27082 can be produced by culturing a WF27082-producing strain
belonging to the *Acremonium* such as *Acremonium* sp. No.27082 in a nutrient
broth and, if necessary, applying chemical modification (e.g. introduction of
25 hydroxy-protective group, etc.).

For example, WF27082 wherein R^4 is hydroxy having hydroxy-protective
group can be prepared by introducing a hydroxy-protective group into the
compound wherein R^4 is hydroxy.

- Suitable introducing agent of the hydroxy-protective group used in this
30 reaction may be a conventional one such as di(lower)alkyl sulfoxide, for example,
lower alkyl methyl sulfoxide (e.g. dimethyl sulfoxide, ethyl methyl sulfoxide, propyl
methyl sulfoxide, isopropyl methyl sulfoxide, butyl methyl sulfoxide, isobutyl
methyl sulfoxide, hexyl methyl sulfoxide, etc.), trisubstituted silyl compound such

as tri(lower)alkylsilyl halide (e.g. trimethylsilyl chloride, triethylsilyl bromide, tributylsilyl chloride, tert-butyl-dimethylsilyl chloride, etc.), lower alkyl-diarylsilyl halide (e.g. methyl-diphenylsilyl chloride, ethyl-diphenylsilyl bromide, propyl-ditolylsilyl chloride, tert-butyl-diphenylsilyl chloride, etc.), and acylating agent
5 which is capable of introducing the acyl group as mentioned before such as carboxylic acid, sulfonic acid and their reactive derivative, for example, an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Preferable example of such reactive derivative may include acid chloride, acid bromide, a mixed acid anhydride with an acid such as substituted phosphoric acid
10 (e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, alkyl carbonate (e.g. methyl carbonate, ethyl carbonate, propyl carbonate, etc.), aliphatic carboxylic acid (e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic
15 trifluoroacetic acid, etc.), aromatic carboxylic acid (e.g. benzoic acid, etc.), a symmetrical acid anhydride, an activated acid amide with a heterocyclic compound containing imino function such as imidazole, 4-substituted imidazole, dimethylpyrazole, triazole and tetrazole, an activated ester (e.g. p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester,
20 mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyridyl ester, piperidinyl ester, 8-quinolyl thioester, or an ester with an N-hydroxy compound such as N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxybenzotriazole, 1-hydroxy-6-chlorobenzotriazole,
25 etc.), and the like.

In this reaction, in case where the di(lower)alkyl sulfoxide is used as an introducing agent of the hydroxy-protective group, the reaction is usually conducted in the presence of lower alkanolic anhydride such as acetic anhydride.

Further, in case where the trisubstituted silyl compound is used as an
30 introducing agent of the hydroxy-protective group, the reaction is preferable conducted in the presence of a conventional condensing agent such as imidazole, and the like.

Still further, in case where the acylating agent is used as an introducing

agent of the hydroxy-protective group, the reaction is preferably conducted in the presence of an organic or inorganic base such as alkali metal (e.g. lithium, sodium, potassium, etc.), alkaline earth metal (e.g. calcium, etc.), alkali metal hydride (e.g. sodium hydride, etc.), alkaline earth metal hydride (e.g. calcium hydride, etc.),
 5 alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal hydrogencarbonate (e.g. sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), alkali metal alkanoic acid (e.g. sodium acetate, etc.), trialkylamine (e.g. triethylamine, etc.), pyridine compound (e.g.
 10 pyridine, lutidine, picoline, 4-N,N-dimethylaminopyridine, etc.), quinoline, and the like.

In case where the acylating agent is used in a free form or its salt in this reaction, the reaction is preferably conducted in the presence of a conventional
 15 condensing agent such as a carbodiimide compound [e.g. N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc.], a ketenimine compound (e.g. N,N'-carbonylbis(2-methylimidazole), pentamethyleneketene-N-cyclohexylimine,
 20 diphenylketene-N-cyclohexylimine, etc.); an olefinic or acetylenic ether compound (e.g. ethoxyacetylene, β -cyclovinyloethyl ether), a sulfonic acid ester of N-hydroxybenzotriazole derivative [e.g. 1-(4-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole, etc.], and the like.

The reaction is usually conducted in a conventional solvent which does not
 25 adversely influence the reaction, such as water, acetone, dichloromethane, alcohol (e.g. methanol, ethanol, etc.), tetrahydrofuran, pyridine, N,N-dimethylformamide, etc., or a mixture thereof, and further in case where the base or the introducing agent of the hydroxy-protective group is in liquid, it can also be used as a solvent.

The reaction temperature is not critical and the reaction is usually conducted
 30 from under cooling to heating.

Characteristics of the producing strain No. 27082

The fungal strain No. 27082 was originally isolated from a soil sample,

collected in Akita-shi, Akita-ken, Japan. This organism grew very restrictedly on various culture media, and formed orange white to dark brown colonies. The strain produced conidial structures consisting of simple phialidic conidiogenous cells and conidia in slimy heads, while it did not form teleomorph on culture media.

5 Its mycological characteristics were as follows.

Cultural characteristics on various agar media are summarized in Table 1. Culture on potato dextrose agar grew very restrictedly, attaining 1.5 - 2.5 cm in diameter four weeks later at 25°C. This colony surface was centrally raised, cottony, radiately sulcate to wrinkly, exudate, brownish orange to grayish brown,
10 but orange white at the margin. Conidial structures were not observed on the media. The reverse color was dark brown, and brown soluble pigments were produced. Colonies on corn meal agar spread at a similar rate as on potato dextrose agar under the same conditions. The surface was plane, thin, powdery, olive at the center and orange white at the margin. Conidial structures were
15 abundantly formed. The reverse was dark brown at the center and grayish orange to grayish brown at the margin, and pale orange soluble pigments were observed.

The morphological characteristics were determined from the cultures on a Miura's LCA plate (Miura, K. and M. Kudo: *Trans. Mycol. Soc. Japan*, 11:116-118,
20 1970). Conidiophores were rarely present, micronematous, short, basitonus, and sometimes verticillate. Conidiogenous cells were discrete, acrogenous, phialidic, and nematogenous to plectonematogenous. They were hyaline, finely roughened, aciculate to subulate, with indistinct collarettes, 21-40 µm long, tapering from (1.5-)2-2.5 µm near the base to 1-2(-2.5) µm at the tip, and
25 producing conidia in slimy drops. Conidia were hyaline at first, becoming dark olivaceous at maturity, smooth, one-celled, broadly ellipsoidal to ellipsoidal, sometimes pyriform, rounded at the tip, with a small projection at the base, and 3.5 - 5(-6) x 2.5 - 3(-3.5) µm in size. Vegetative hyphae were hyaline, smooth, septate and branched. The hyphal cells were cylindrical, 2-3 µm in width.
30 Chlamydospores were not observed.

Strain No. 27082 was able to grow in the temperature range of from 2 to 26°C, with the growth optimum at 21 to 22°C. These temperature data were determined on potato dextrose agar (made by NISSUI).

On the basis of the morphological characteristics as compared with fungal taxonomic criteria by von Arx (J. A. von Arx: The Genera of Fungi - Sporulating in Pure Culture. 3rd ed., pp.315, J. Cramer, Vaduz, 1974) and Domsch *et al.* (K. H. Domsch, W. Gams and T. -H. Anderson: Compendium of Soil Fungi. Vol. 1, pp.859, Academic Press, London, 1980), strain No. 27082 was considered to belong to the hyphomycete genus *Acremonium* Link (1809). Thus, we identified this isolate as one strain of the genus *Acremonium*, and named it *Acremonium* sp. No. 27082. The strain has been deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan, as FERM BP-6539 (deposition date: October 2, 1998).

Table 1. Cultural characteristics of strain No. 27082.

Media	Cultural characteristics
5 Malt extract agar*	G: Very restrictedly, 1.5-2.5 cm S: Circular, plane, felty to cottony, formed some conidial structures, olive brown (4D3-4E3) at the center, orange white (6A2) or grayish orange (6B4-6B5) at the margin
10	R: Brown (7E8) at the center, pale orange (5A3) at the margin
Potato dextrose agar (Difco 0013)	G: Very restrictedly, 1.5-2.5 cm S: Circular, centrally raised, cottony, radiately sulcate to wrinkly, exudate, formed no conidial structures, brownish orange (7C4) to grayish brown (7D3), and orange white (6A2) at the margin R: Dark brown (7F7-7F8), and producing brown soluble pigments
15	
Czapek's solution agar*	G: Very restrictedly, 1.5-2.5 cm S: Circular to irregular, plane to centrally raised, submerged at the margin, formed no conidial structures, dark brown (7F6) or orange white (6A2) at the center, yellowish white (4A2) at the margin, and brown (6E6-6E8) at the middle
20	
25	R: Dark brown (6F5-6F7), and yellowish white (4A2) at the margin
Sabouraud dextrose agar (Difco 0190)	G: Very restrictedly, 1.5-2.0 cm S: Circular, centrally raised, felty, radiately sulcate to wrinkly, formed no conidial structures, grayish orange (6B4-6B5) at the center, and light brown (6D6) to brown (6E6) at the margin R: Brown (7E7) to dark brown (7F7), and producing brown soluble pigments
30	

	Emerson Yp Ss agar (Difco 0739)	G: Very restrictedly, 1.5-2.5 cm S: Circular, plane, felty, exudate, formed no conidial structures, orange white (5A2), and light brown (6D6-6D7) at the margin
5	Corn meal agar (Difco 0386)	R: Light brown (6D7) to dark brown (6F7) G: Very restrictedly, 1.5-2.5 cm S: Circular, plane, thin, powdery, formed conidial structures abundantly, olive (3F5-3F6) at the center, and orange white (6A2) at the margin
10	MY20 agar*	R: Dark brown (7F7) at the center, grayish orange (5B4) to grayish brown (5D3) at the margin, and producing of pale orange soluble pigments G: Very restrictedly, 1.5-2.5 cm S: Circular, centrally raised, cottony to floccose, radiately sulcate, formed no conidial structures, and grayish orange (6B4-6B6) at the center, and orange white (5A2) at the margin R: Light brown (6D7-6D8), and light orange (5A5) at the margin
20	Oatmeal agar (Difco 0552)	G: Very restrictedly, 1.5-2.5 cm S: Circular, plane, felty to cottony, radiately sulcate, formed some conidial structures, dull green (30D4-30E4) at the center, orange white (6A2) at the margin, and producing grayish brown soluble pigments
25		

Abbreviation G: growth, measuring colony size in diameter,
 S: colony surface, R: reverse.

*: The compositions of malt extract agar, Czapek's solution agar and MY20 agar are based on JCM Catalogue of Strains (Nakase, T., 6th ed., pp.617, Japan Collection of Microorganisms, the Institute of Physical and Chemical Research, Saitama, 1995).

These characteristics were observed after 28 days of incubation at 25°C. The color descriptions are based on Methuen Handbook of Colour (Kornerup, A. and J. H. Wanscher, 3rd ed., pp.252, Methuen, London, 1978).

It is to be understood that the production of the WF27082 is not limited to the use of the particular organism described herein, which is given for the illustrative purpose only. This invention also includes the use of any mutants which are capable of producing the WF27082 including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as recombinant DNA technology, irradiation of X-ray, ultra-violet radiation, treatment with N-methyl-N'-nitro-N-nitrosoguanidine, 2-aminopurine, and the like.

Production of the WF27082

Of the compounds of the above formula (I), the WF27082 is produced when the WF27082-producing strain belonging to the *Acremonium* is grown in a nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e.g. shaking culture, submerged culture, etc.).

The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose or glycerin, or the like.

The preferred sources of nitrogen are peanut powder, yeast extract, beef extract, peptone, polypeptone, gluten meal, cotton seed flour, soybean powder, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or amino acid, or the like.

The carbon and nitrogen sources, though advantageously employed in combination, need not be used in their pure form because less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.

When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salts, iron salts, or cobalt salts, or the like.

If necessary, especially when the culture medium foams seriously, a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil, silicone, or the like may be added.

Agitation and aeration of the culture mixture may be accomplished in a variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, and the like.

The fermentation is usually conducted at a temperature between about 10°C and 40°C, preferably 20°C to 30°C, for a period of about 50 hours to 150 hours, which may be varied according to fermentation conditions and scales.

The resultant culture broth is then subjected for recovery of the WF27082 to various procedures conventionally used for recovery and purification of biological active substances, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.

Of the compounds of the formula (I), the compound wherein R¹ is methyl, R² is methyl, R³ is hydrogen and R⁴ is hydroxy or protected hydroxy (e.g. FR235220) can be prepared, for example, according to the method described in JP-A-7-196686. It can be also obtained by preparing WF27082 as mentioned above and modifying the necessary part. This modification can be performed according to a method known per se.

WF27082 can be in the form of a solvate, which is within the scope of the present invention. The solvate preferably includes a hydrate and an ethanolate.

As examples for showing biological activities of the compounds of the above formula (I), some biological data are shown in the following.

25

Test 1. Effect on lymphocyte blastogenic response

WF27082B and FR235220 were used as test compounds.

The lymphocyte blastogenesis test was performed in microtiter plates with each well containing 1 x 10⁵ splenic cells of Balb/c mice in 0.1 ml RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 50 mM 2-mercaptoethanol, penicillin (100 units/ml) and streptomycin (100 µg/ml), to which anti-CD3 antibody (2C11) (1 µg/ml) was added. The cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ for 72 hours. After the culture

period, suppressive activities of the test samples in lymphocyte blastogenesis were quantified by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)] dye reduction assay.

WF27082 B was dissolved in methanol and further diluted in RPMI-1640 medium and added to the culture to give final concentrations of 50 ng/ml or less. FR235220 was dissolved in methanol and further diluted in RPMI-1640 medium and added to the culture to give final concentrations of 500 ng/ml or less. The results are shown in Table 2 and Table 3, respectively.

As shown in Tables 2 and 3, WF27082 B and FR235220 suppressed murine lymphocyte blastogenesis induced by anti-CD3 antibody in a dose-dependent manner. WF27082 B was found to have particularly strong effect.

Table 2 Effect of WF27082 B on murine lymphocyte blastogenesis induced by anti-CD3 antibody

15

Concentration (ng/ml)	50	25	12.5	6.3	3.1	1.6	0.8
Inhibition (%)	113.5	114.1	111.7	86.6	46.1	19.3	4.4

Table 3 Effect of FR235220 on murine lymphocyte blastogenesis induced by anti-CD3 antibody

Concentration (ng/ml)	500	250	125	63	31	16	8	4
Inhibition (%)	126.0	126.0	127.2	125.3	106.0	45.1	-1.3	-23.4

20

Test 2. Effect of WF27082 B on DTH (delayed type hypersensitivity) response in mice

Female Balb/c mice were immunized with sheep red blood cells (1×10^8) by subcutaneous injection. WF27082 B was dissolved in 10% aqueous HCO-60 and administered orally for 8 consecutive days, beginning at one day before the

25

immunization. Six days after the immunization, sheep red blood cells (1.25×10^8) were injected into right rear footpad, and 24 hours later, footpad swelling was measured with dial guage (Ozaki MFG Co., Ltd.). The magnitude of the DTH was expressed as the thickness of the challenged right footpad as compared with the untreated left footpad.

As shown in Table 4, the footpad swelling was markedly suppressed by the administration of WF27082 B in a dose-dependent manner without any body weight loss.

Table 4. Effect of WF27082 B on DTH response in mice

	N	Dose (mg/kg)	Footpad swelling (% Inhibition)	Body weight gain (g)
unprimed	5		100***	1.2 ± 0.2
primed	10		0	1.2 ± 0.2
WF27082 B	5	10	20	1.5 ± 0.2
	5	32	34**	1.5 ± 0.3
	5	100	47***	1.1 ± 0.3

** : $P < 0.01$

*** : $P < 0.001$

Test 3. Effect on activity of partially purified human histone deacetylase

The partial purification of human histone deacetylase, the preparation of [^3H] acetyl histones, and the assay for histone deacetylase activity were basically performed according to the method as proposed by Yoshida *et al.* as follows.

Partial Purification of Human Histone Deacetylase - The human histone deacetylase was partially purified from human T cell leukemia Jurkat cells.

Jurkat cells (5×10^8 cells) were suspended in 40 ml of the HDA buffer consisting of 15 mM potassium phosphate, pH 7.5, 5% glycerol and 0.2 mM EDTA. After homogenization, nuclei were collected by centrifugation ($35,000 \times g$, 10 min) and homogenized in 20 ml of the same buffer supplemented with 1 M $(\text{NH}_4)_2\text{SO}_4$. The viscous homogenate was sonicated and clarified by centrifugation ($35,000 \times g$, 10 min), and the deacetylase was precipitated by raising the concentration of $(\text{NH}_4)_2\text{SO}_4$ to 3.5 M. The precipitated protein was dissolved in 10 ml of the HDA

buffer and dialyzed against 4 liters of the same buffer. The dialyzate was then loaded onto a DEAE-cellulose (Whatman DE52) column (25 x 85 mm) equilibrated with the same buffer and eluted with a linear gradient (0-0.6 M) of NaCl (300 ml). A single peak fraction of histone deacetylase activity was eluted between 0.3 and 0.4 M NaCl.

Preparation of [^3H] Acetyl Histones - To obtain [^3H]acetyl-labeled histones as the substrate for the histone deacetylase assay, 1×10^8 cells of Jurkat in 20 ml of RPMI-1640 medium supplemented with 10% FBS, penicillin (50 units/ml) and streptomycin (50 $\mu\text{g}/\text{ml}$) were incubated with 300 MBq [^3H] sodium acetate in the presence of 5 μM sodium butyrate for 30 min in 5% CO_2 -95% air atmosphere at 37°C in a 75 cm^2 flask, harvested into a centrifuge tube (50 ml), collected by centrifugation at 1000 rpm for 10 min, and washed once with phosphate-buffered saline. The washed cells were suspended in 15 ml of ice-cold lysis buffer (10 mM Tris-HCl, 50 mM sodium bisulfite, 1% Triton X-100, 10 mM MgCl_2 , 8.6% sucrose, pH 6.5). After Dounce homogenization (30 stroke), the nuclei were collected by centrifugation at 1000 rpm for 10 min, washed three times with 15 ml of the lysis buffer, and once with 15 ml of ice-cold washing buffer (10 mM Tris-HCl, 13 mM EDTA, pH 7.4) successively. The pellet was suspended in 6 ml of ice-cold water using a mixer, and 68 ml of H_2SO_4 was added to the suspension to give a concentration of 0.4 N. After incubation at 4°C for 1 hour, the suspension was centrifuged for 5 min at 15,000 rpm, and the supernatant was taken and mixed with 60 ml of acetone. After overnight incubation at -20°C, the coagulated material was collected by microcentrifugation, air-dried, and stored at -8°C.

Assay for Histone Deacetylase Activity - For the standard assay, 10 μl of [^3H]acetyl-labeled histones was added to 90 μl of the enzyme fraction, and the mixture was incubated at 25°C for 30 min. The reaction was stopped by addition of 10 μl of HCl. The released [^3H]acetic acid was extracted with 1 ml of ethyl acetate, and 0.9 ml of the solvent layer was taken into 10 ml of toluene scintillation solution for determination of radioactivity.

As shown in Table 5, WF27082 B, E and F, and FR235220 potently inhibited the activity of partially purified human (Jurkat cells) histone deacetylase in a dose-dependent manner.

Table 5 Effect on activity of partially purified human histone deacetylase

Concentration (ng/ml)		1000	100	10	1
Inhibition (%)	WF27082 B	98.6	76.5	37.3	1.9
	WF27082 E	104.9	88.5	57.6	11.1
	WF27082 F	91.7	74.1	36.5	11.4
	FR235220	94.6	74.6	33.7	-13.1

Test 4. Antitumor activities of WF27082 B against human tumor cell lines

5 The cytotoxic activity of WF27082 B against human tumor cell lines was determined *in vitro* as follows. Concentration of the compound required for 50% inhibition of cell growth (IC₅₀; ng/ml) was examined by plotting the logarithms of the concentration *vs.* the growth rate (percentage of control) of the treated cells. Human T cell leukemia Jurkat cells (1 x 10⁵ cells/ml) and human colon

10 adenocarcinoma HT-29 cells (5 x 10⁴ cells/ml) were treated with WF27082 B in 100 µl of RPMI-1640 medium supplemented with 10% FBS, penicillin (50 units/ml) and streptomycin (50 µg/ml) in 5% CO₂-95% air atmosphere at 37°C. The cytotoxicity was colorimetrically determined at 550 nm (and 660 nm as a reference) according to the MTT method described above.

15 The result is shown in Table 6. WF27082 B had potent antitumor activities against Jurkat cells and HT-29 cells.

Table 6 Antitumor activities of WF27082 B against human tumor cell lines (*in vitro*)

20

IC50 (ng/ml)	
Jurkat	HT-29
11	14

The pharmaceutical composition of this invention comprising histone deacetylase inhibitor, such as the compound of the formula (I), is useful as a therapeutic or prophylactic agent for diseases caused by abnormal gene

expression such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infection or the like. Further, it is useful as an antitumor agent and immunosuppressant, which prevents an organ transplant rejection and autoimmune diseases as exemplified below.

- 5 Rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; graft-versus-host reactions following bone marrow transplantation;
- 10 autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, etc.; and infections caused by pathogenic microorganisms (e.g. *Aspergillus fumigatus*, *Fusarium oxysporum*, *Trichophyton asteroides*, etc.).

- 15 Furthermore, pharmaceutical preparations of the histone deacetylase inhibitor, such as the compound of the formula (I), are useful for the therapy and prophylaxis of the following diseases.

- Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases (e.g. psoriasis, atopic
- 20 dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, and alopecia areata); autoimmune diseases of the eye (e.g. keratoconjunctivitis, vernal conjunctivitis,
- 25 uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.);
- 30 reversible obstructive airways diseases [asthma (e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and dust asthma), particularly chronic or inveterate asthma (e.g. late asthma and airway hyper-responsiveness) bronchitis, etc.] ;

- mucosal or vascular inflammations (e.g. gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with thermal burns, leukotriene B4-mediated diseases);
- 5 intestinal inflammations / allergies (e.g. coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis);
food-related allergic diseases with symptomatic manifestation remote from the gastrointestinal tract (e.g. migraine, rhinitis and eczema);
renal diseases (e.g. interstitial nephritis, Goodpasture's syndrome, hemolytic
- 10 uremic syndrome, and diabetic nephropathy);
nervous diseases (e.g. multiple myositis, Guillain-Barre syndrome, Meniere's disease, multiple neuritis, solitary neuritis, cerebral infarction, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and radiculopathy);
cerebral ischemic diseases (e.g., head injury, hemorrhage in brain (e.g.,
- 15 subarachnoid hemorrhage, intracerebral hemorrhage), cerebral thrombosis, cerebral embolism, cardiac arrest, stroke, transient ischemic attack (TIA), and hypertensive encephalopathy);
endocrine diseases (e.g. hyperthyroidism, and Basedow's disease);
hematic diseases (e.g. pure red cell aplasia, aplastic anemia,
- 20 hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, and anerythroplasia);
bone diseases (e.g. osteoporosis);
respiratory diseases (e.g. sarcoidosis, pulmonary fibrosis, and idiopathic
- 25 interstitial pneumonia);
skin diseases (e.g. dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photosensitivity, and cutaneous T-cell lymphoma);
circulatory diseases (e.g. arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, and myocarditis);
- 30 collagen diseases (e.g. scleroderma, Wegener's granuloma, and Sjögren's syndrome);
adiposis;
eosinophilic fasciitis;

- periodontal diseases (e.g. damage to gingiva, periodontium, alveolar bone or substantia ossea dentis);
- nephrotic syndrome (e.g. glomerulonephritis);
- male pattern alopecia, alopecia senile;
- 5 muscular dystrophy;
- pyoderma and Sezary syndrome;
- chromosome abnormality-associated diseases (e.g. Down's syndrome);
- Addison's disease;
- active oxygen-mediated diseases [e.g. organ injury (e.g. ischemic circulation
- 10 disorders of organs (e.g. heart, liver, kidney, digestive tract, etc.) associated with preservation, transplantation, or ischemic diseases (e.g. thrombosis, cardiac infarction, etc.)];
- intestinal diseases (e.g. endotoxin shock, pseudomembranous colitis, and drug- or radiation-induced colitis);
- 15 renal diseases (e.g. ischemic acute renal insufficiency, chronic renal failure);
- pulmonary diseases (e.g. toxicosis caused by pulmonary oxygen or drugs (e.g. paracort, bleomycin, etc.), lung cancer, and
- pulmonary emphysema);
- ocular diseases (e.g. cataracta, iron-storage disease (siderosis bulbi), retinitis,
- 20 pigmentosa, senile plaques, vitreous scarring, corneal alkali burn):
- dermatitis (e.g. erythema multiforme, linear immunoglobulin A bullous dermatitis, cement dermatitis);
- and other diseases (e.g. gingivitis, periodontitis, sepsis, pancreatitis, and diseases caused by environmental pollution (e.g. air pollution), aging, carcinogen,
- 25 metastasis of carcinoma, and hypobaropathy));
- diseases caused by histamine release or leukotriene C4 release;
- restenosis of coronary artery following angioplasty and prevention of postsurgical adhesions;
- Autoimmune diseases and inflammatory conditions (e.g., primary mucosal edema,
- 30 autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g.

arthritis deformans), or polychondritis);
Human Immunodeficiency Virus (HIV) infection, AIDS;
allergic conjunctivitis;
hypertrophic cicatrix and keloid due to trauma, burn, or surgery.

- 5 Therefore, the pharmaceutical composition of the present invention is useful for the therapy and prophylaxis of liver diseases [e.g. immunogenic diseases (e.g. chronic autoimmune liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis or sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock, or anoxia),
10 hepatitis B, non-A non-B hepatitis, hepatocirrhosis, and hepatic failure (e.g. fulminant hepatitis, late-onset hepatitis and "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases))].

- The pharmaceutical composition of this invention can be used in the form of pharmaceutical preparation, for example, in a solid, semisolid or liquid form,
15 which contains the histone deacetylase inhibitor, such as the compound of the formula (I), as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories,
20 solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.

- The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in
25 manufacturing preparations, in a solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.

- For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, topical or oral administration. While the dosage of
30 therapeutically effective amount of the histone deacetylase inhibitor, such as the compound of the formula (I), varies from and also depends upon the age and condition of each individual patient to be treated, when an individual patient is to be treated, in the case of intravenous administration, a daily dose of 0.01 - 10 mg

of the histone deacetylase inhibitor, such as the compound of the formula (I), per kg weight of human being, in the case of intramuscular administration, a daily dose of 0.1 - 10 mg of the histone deacetylase inhibitor, such as the compound of the formula (I), per kg weight of human being, and in the case of oral
5 administration, a daily dose of 0.5 - 50 mg of the histone deacetylase inhibitor, such as the compound of the formula (I), per kg weight of human being, is generally given for treatment.

Following examples are given for the purpose of illustrating the present invention in more detail.

10 Example 1

(1) Fermentation production of WF27082 B:

An aqueous seed medium (30 ml) containing 4.0% sucrose, 1.0% glucose, 2.0% soluble starch, 3.0% cotton seed flour, 1.5% soybean flour, 1.0% KH_2PO_4 , 0.2% CaCO_3 , 0.05% Adekanol LG-109 (defoaming agent, Asahi Denka Co., Ltd.)
15 and 0.05% Silicone KM-70 (defoaming agent, Shin-Etsu Chemical Co., Ltd.) was poured into a 100-ml Erlenmeyer flask and sterilized at 120°C for 30 minutes. A loopful of fungus strain No. 27082 was inoculated from a slant culture into the flask and cultured at 25°C on a rotary shaker at 220 rpm (5.1 cm-throw) for 4 days. The seed culture (6 ml) was inoculated to 20 liters of sterile production medium
20 consisting of 3.0% modified starch, 2.0% cotton seed flour, 0.2% wheat germ, 0.1% KH_2PO_4 , 0.1% NaCl, 0.0005% $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 0.05% Adekanol LG-109 and 0.05% Silicone KM-70 (pH 7.0) in a 30-liter jar fermentor. Fermentation was carried out at 25°C for 4 days under aeration at 20 liters/min and agitation at 200 - 300 rpm.

25

(analytical HPLC conditions)

column	YMC Pack ODS-AM AM303, S-5 120A (250mm L. x 4.6mm I.D., YMC Co., Ltd.)
eluent	50% aqueous acetonitrile
30 flow rate	1 ml/min.
detection	UV at 210nm
retention time	WF27082 B 10.4 min.

(2) Isolation of WF27082 B :

The cultured broth (20L: containing 380 mg of WF27082 B) was extracted with 20L of acetone by intermittent mixing. The acetone extract was filtered with the aid of diatomaceous earth and diluted with the same volume of water. The
5 diluted filtrate was passed through a column (1L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with water and 70% aqueous methanol, and eluted with methanol. The eluate (1L) was diluted with 2L of water and applied on a column (180 ml) of YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.) packed with 45% aqueous acetonitrile. The column was eluted with 45%
10 aqueous acetonitrile and elution was monitored by analytical HPLC indicated above. The portion corresponding to the WF27082 B was concentrated *in vacuo* to give an aqueous residue. This residue was extracted with ethyl acetate and the extracts were concentrated *in vacuo* to give an oily residue (containing 351 mg of WF27082 B). The oily residue was dissolved in a small volume of methanol,
15 mixed with 20 ml of silica gel 60 (70-230 mesh, MERCK), and concentrated to dryness. The dry powder was subjected to column chromatography using the same silica gel 60 (230 ml) which was packed with chloroform. The column was eluted with chloroform and elution was monitored by analytical HPLC indicated above. The portion corresponding to the purified WF27082 B was concentrated
20 *in vacuo* to give 230 mg of a colorless oil.

Example 2

(1) Fermentation production of WF27082 E and F:

The cultured broth (20L) was obtained in substantially the same manner as
25 in Example 1 (1).

(2) Isolation of WF27082 E and F :

The cultured broth (20L) was extracted with 20L of acetone by intermittent mixing. The acetone extract was filtered with the aid of diatomaceous earth and diluted with the same volume of water. The diluted filtrate was passed through a
30 column (1L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with water and 70% aqueous methanol, and eluted with methanol. The eluate (1L) was diluted with 2L of water and applied on a column (180 mL) of YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.) packed with 45% aqueous acetonitrile.

The column was eluted with 45% aqueous acetonitrile and elution was monitored by analytical HPLC indicated below. The portion corresponding to the mixture of WF27082 E and F (500 mL) was diluted with 500 mL of water and applied on a column (180 mL) of YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.) packed with 60% aqueous methanol. The column was eluted with 60% aqueous methanol and the portion corresponding to the mixture of WF27082 E and F was concentrated in vacuo to give an aqueous residue. This residue was extracted with ethyl acetate and the extracts were concentrated in vacuo to give an oily residue. The oily residue was dissolved in a small volume of methanol and subjected to preparative HPLC, and applied to packed column Fluofix 120E 1EW225 (20mm x 250mm, NEOS Co., Ltd.) with 40% aqueous methanol as mobile phase and at flow rate 9.9 ml/min. The portion corresponding to the purified WF27082 E and F (retention: WF27082 E; 74.8 min, WF27082 F; 85.7 min) was concentrated in vacuo to give 8 mg and 18 mg in the form of an oily residue, respectively.

15


(analytical HPLC conditions)

column	YMC Pack ODS-AM AM303, S-5 120A (250mm L. x 4.6mm I.D., YMC Co., Ltd.)
eluent	40% aqueous acetonitrile
temperature	50°C
flow rate	1 ml/min.
detection	UV at 210nm
retention time	WF27082 E 15.3 min. WF27082 F 16.1 min.

25

This application is based on Application No. 6469/1998 and Application No. 9257/1999 filed in Australia, the content of which is incorporated hereinto by reference.

1. A WF27082 compound of the formula :



wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group, providing that when R³ is hydrogen, R² is ethyl.


2. A WF27082 compound of Claim 1, wherein R¹ is methyl, R² is ethyl, R³ is methyl and R⁴ is hydroxy.

3. A fungal strain belonging to the genus *Acremonium*, which has a deposit number FERM BP-6539 and which produces a compound having a histone deacetylase inhibitory activity.

4. A compound having a histone deacetylase inhibitory activity, which is obtained by culturing the fungal strain of Claim 3 in a nutrient medium and recovering the compound from a culture broth thereof.

5. A process for producing the WF27082 compound of Claim 1, which comprises culturing, in a nutrient medium, a WF27082-producing strain belonging to the genus *Acremonium* and recovering the compound from a culture broth thereof.

6. The process of Claim 5, wherein the WF27082-producing strain belonging to the genus *Acremonium* is the fungal strain of Claim 3.
7. A pharmaceutical composition containing the WF27082 compound of Claim 1 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
8. A compound of Claim 1 for use as a medicament.
9. A process for producing a compound having a histone deacetylase inhibitory activity, which comprises culturing, in a nutrient medium, a fungal strain belonging to the genus *Acremonium*, which produces a compound having a histone deacetylase inhibitory activity, and recovering said compound.
10. A compound having a histone deacetylase inhibitory activity, which is obtained by culturing, in a nutrient medium, a fungal strain belonging to the genus *Acremonium*, which produces a compound having a histone deacetylase inhibitory activity, and recovering the compound from a culture broth thereof.
11. A histone deacetylase inhibitor comprising a compound of the formula (I):




wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having hydroxy-protective group.

12. A method for inhibiting histone deacetylase, comprising using a compound (I) used in Claim 11.

13. A use of compound (I) used in Claim 11 for the manufacture of a medicament
5 for inhibiting histone deacetylase.

14. A pharmaceutical composition for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections or
10 autoimmune diseases, which comprises, as an active ingredient, a compound of the formula (I):



wherein R¹ is methyl, R² is methyl or ethyl, R³ is hydrogen or methyl and R⁴ is hydroxy optionally having a hydroxy-protective group.

15. A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), or organ transplant rejections, autoimmune diseases, which comprises administering a compound (I) used in Claim 14 to a
15 human being or an animal.

20

16. A use of a compound (I) used in Claim 14 for the manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic

leukaemia (APL), organ transplant rejections or autoimmune diseases.

17. A method for treating or preventing protozoal infections or tumors, which comprises administering a compound WF 27082 used in Claim 1 to a human
5 being or an animal.

18. A use of a compound WF27082 used in Claim 1 for the manufacture of a medicament for treating or preventing protozoal infections or tumors.

10 19. A use of a histone deacetylase inhibitor as an immunosuppressant or an antitumor agent.

20. A use of a histone deacetylase inhibitor for the manufacture of a medicament for treating or preventing organ transplant rejections, autoimmune diseases or
15 tumors.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 5/12, C12P 21/04, C12R 1/645, A61K 38/12, A61P 33/02, 35/00, 37/00	A3	(11) International Publication Number: WO 00/21979 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/JP99/05597 (22) International Filing Date: 8 October 1999 (08.10.99) (30) Priority Data: PP 6469 13 October 1998 (13.10.98) AU PP 9257 16 March 1999 (16.03.99) AU (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): MORI, Hiroaki [JP/JP]; 5-20-205, Ohmachi, Tsuchiura-shi, Ibaraki 300-0038 (JP). SAKAMOTO, Kazutoshi [JP/JP]; 17-14, Ottominami 2-chome, Tsuchiura-shi, Ibaraki 300-0845 (JP). TSURUMI, Yasuhisa [JP/JP]; 3-19-1-3-301, Azuma, Tsukuba-shi, Ibaraki 305-0031 (JP). TAKASE, Shigehiro [JP/JP]; 1-12-10, Sousya, Ishioka-shi, Ibaraki 315-0016 (JP). HINO, Motohiro [JP/JP]; 13-3-1003, Touzaki-cho, Tsuchiura-shi, Ibaraki 300-0031 (JP).	(74) Agent: TAKASHIMA, Hajime; Yuki Building, 3-9, Hiranomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0046 (JP). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 20 July 2000 (20.07.00)	
(54) Title: CYCLIC TETRAPEPTIDE AND THEIR USE AS HISTONE DEACETYLASE INHIBITOR (57) Abstract <p>A cyclic tetrapeptide compound and use thereof. Especially, a compound WF27082, a process for production of the compound by culturing, in a nutrient medium, a WF27082-producing strain belonging to <i>Acremonium</i> and recovering the compound from a culture broth, a pharmaceutical composition containing the compound as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient, the compound for use as a medicament, a use of the compound for manufacture of a medicament for inhibiting histone deacetylase, a use of the compound for manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infections, organ transplant rejections, autoimmune diseases, or tumors, a use of histone deacetylase inhibitors as an immunosuppressant or an antitumor agent, and a use of histone deacetylase inhibitors for manufacture of a medicament for treating or preventing organ transplant rejections, autoimmune diseases or tumors are described.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/05597

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K5/12 C12P21/04 C12R1/645 A61K38/12 A61P33/02
 A61P35/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 11366 A (MERCK & CO INC ;DULSKI PAULA M (US); GURNETT ANNE M (US); MYERS RO) 27 March 1997 (1997-03-27) The whole document; see especially page 6 and claim 14	1-20
A	GB 2 309 696 A (MERCK & CO INC) 6 August 1997 (1997-08-06) The whole document; see especially page 9 --- -/--	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

4 February 2000

Date of mailing of the international search report

16. 05 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

GROENENDIJK, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/05597

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 199540 Derwent Publications Ltd., London, GB; Class 802, AN 1995-304271 XP002129775 & JP 07 196686 A (TAKEDA CHEM IND LTD), 1 August 1995 (1995-08-01) cited in the application abstract</p> <p>---</p>	
A	<p>WO 97 35990 A (JAMISON TIMOTHY F ;HARVARD COLLEGE (US); TAUNTON JACK (US); HASSIG) 2 October 1997 (1997-10-02) the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 99/05597

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12,15,17,19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 4,9,10(partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-3,5-8,17,18 (complete); 4,9-16,19,20 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 4,9,10(partially)

Present claims 4,9 and 10 relate to a compound or its preparation defined by reference to a desirable characteristic or property, namely a histone deacetylase inhibitory activity. The process of claim 9 is only described in terms of the compounds to be obtained and does not itself define said compounds.

These claims cover all compounds (and processes for their preparation) having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (see claim 1). In the present case, said claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds and also the process for their preparation by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in claim 1, their preparation and use.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-3,5-8,17,18(all complete),4,9-16,19,
20(all partially)

Compounds as defined in claim 1, their preparation, their
compositions and use and a strain as defined in claim 3,

2. Claims: 11-16,19,20(all partially)

Compositions as defined in claims 11 and 14 as far as
relating to a compound according to the formula of claim 11
wherein R3 is hydrogen and R2 is methyl and their use

3. Claims: 19,20(all partially)

Use as defined in the claims 19 and 20 as far as not
encompassed by the subjects 1 and 2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/05597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9711366 A	27-03-1997	AU 712801 B	18-11-1999
		AU 6979096 A	09-04-1997
		CA 2231251 A	27-03-1997
		EP 0855024 A	29-07-1998
		JP 11514857 T	21-12-1999
		US 5922837 A	13-07-1999
GB 2309696 A	06-08-1997	US 5922837 A	13-07-1999
JP 7196686 A	01-08-1995	NONE	
WO 9735990 A	02-10-1997	AU 2990597 A	17-10-1997

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.